Mesenchymal stem cells-based therapy in liver diseases

Han, Hengtong; Jin, Weilin; Li, Xun

doi:10.1186/s43556-022-00088-x

Cited by 6 publications

(4 citation statements)

References 602 publications

(571 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 ). Nevertheless, MSCs vary in their characteristics depending on the origin of cells and tissues as well as culture conditions [ 98 ]. MSCs are in vitro progenitor cells that exhibit plastic adhesion capabilities and a fibroblast-like appearance.…”

Section: Diverse Cell Sources and Therapeutic Sites For Cell Therapymentioning

confidence: 99%

Cell therapy in end-stage liver disease: replace and remodel

Chen

Wu³

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

Liver disease is prevalent worldwide. When it reaches the end stage, mortality rises to 50% or more. Although liver transplantation has emerged as the most efficient treatment for end-stage liver disease, its application has been limited by the scarcity of donor livers. The lack of acceptable donor organs implies that patients are at high risk while waiting for suitable livers. In this scenario, cell therapy has emerged as a promising treatment approach. Most of the time, transplanted cells can replace host hepatocytes and remodel the hepatic microenvironment. For instance, hepatocytes derived from donor livers or stem cells colonize and proliferate in the liver, can replace host hepatocytes, and restore liver function. Other cellular therapy candidates, such as macrophages and mesenchymal stem cells, can remodel the hepatic microenvironment, thereby repairing the damaged liver. In recent years, cell therapy has transitioned from animal research to early human studies. In this review, we will discuss cell therapy in end-stage liver disease treatment, especially focusing on various cell types utilized for cell transplantation, and elucidate the processes involved. Furthermore, we will also summarize the practical obstacles of cell therapy and offer potential solutions.

show abstract

Section: Diverse Cell Sources and Therapeutic Sites For Cell Therapymentioning

confidence: 99%

Cell therapy in end-stage liver disease: replace and remodel

Chen

Wu³

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…Liver disease is the main global health problem leading to death and disability, with approximately 2 million deaths worldwide each year [ 195 ]. Yan et al confirmed that extracellular vesicles derived from hucMSC can alleviate oxidative stress and cell apoptosis through delivering derived glutathione peroxidase 1 (GPX1) to detoxify CCl 4 and H 2 O 2 , thereby promoting the recovery of hepatic oxidative injury [ 196 ].…”

Section: Application Of Stem Cell Evs In Disease Treatmentmentioning

confidence: 99%

Bio-Inspired Nanocarriers Derived from Stem Cells and Their Extracellular Vesicles for Targeted Drug Delivery

Abudurexiti,

Zhao,

Wang

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

With their seemingly limitless capacity for self-improvement, stem cells have a wide range of potential uses in the medical field. Stem-cell-secreted extracellular vesicles (EVs), as paracrine components of stem cells, are natural nanoscale particles that transport a variety of biological molecules and facilitate cell-to-cell communication which have been also widely used for targeted drug delivery. These nanocarriers exhibit inherent advantages, such as strong cell or tissue targeting and low immunogenicity, which synthetic nanocarriers lack. However, despite the tremendous therapeutic potential of stem cells and EVs, their further clinical application is still limited by low yield and a lack of standardized isolation and purification protocols. In recent years, inspired by the concept of biomimetics, a new approach to biomimetic nanocarriers for drug delivery has been developed through combining nanotechnology and bioengineering. This article reviews the application of biomimetic nanocarriers derived from stem cells and their EVs in targeted drug delivery and discusses their advantages and challenges in order to stimulate future research.

show abstract

“…Liver regeneration after surgical resection, one of the distinctive characteristics of the liver, is very important in preventing PHLF. Understanding the predictive markers associated with post-hepatectomy liver regeneration could contribute to developing risk-adapted strategies, increasing the safety of hepatectomies, and avoiding postoperative liver insufficiency and even mortality [ 5 , 6 ]. However, most studies focused on liver examining regeneration are limited to malignant liver diseases [ [7] , [8] , [9] , [10] ], and few reports have examined liver regeneration after surgery for benign liver disease.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of liver regeneration after hemi-hepatectomy by combining computed tomography and post-operative liver function

Shu,

Song,

Lin

et al. 2024

Heliyon

View full text Add to dashboard Cite

Mesenchymal stem cells-based therapy in liver diseases

Cited by 6 publications

References 602 publications

Cell therapy in end-stage liver disease: replace and remodel

Cell therapy in end-stage liver disease: replace and remodel

Bio-Inspired Nanocarriers Derived from Stem Cells and Their Extracellular Vesicles for Targeted Drug Delivery

Evaluation of liver regeneration after hemi-hepatectomy by combining computed tomography and post-operative liver function

Contact Info

Product

Resources

About